You are here

Development of cGMP Manufacturing Process for CBD

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44DA038932-01
Agency Tracking Number: R44DA038932
Amount: $224,841.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: PA14-071
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
WOBURN, MA 01801-1720
United States
DUNS: 194643722
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (781) 932-6933
Business Contact
Phone: (781) 932-6933
Research Institution

DESCRIPTION (provided by applicant): Medical marijuana is now approved in 20 states and the District of Columbia for several medical conditions such as cachexia, cancer, chronic pain, epilepsy and other disorders characterized by seizures, glaucoma, HIV, AIDS, Multiple Sclerosis, muscle spasticity and nausea. Progress has been made on several fronts on the use of cannabinoids for medical use such as Charlotte's Web (CW) being used for childhood epilepsy through ad hoc development by patient advocacy groups.Sativex (GW Pharmaceuticals, England), a drug containing equal proportions of ?9-THC and CBD, was recently approved as a second-line treatment for Multiple Sclerosis (MS) associated spasticity in Canada, New Zealand and 8 European countries. The ready availability of pharmaceutical-grade CBD and a standardized CW product, manufactured following cGMP guidelines, will facilitate clinical evaluation by NIH investigators and other researchers for epilepsy, MS and other CNS diseases. The developed process will

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government